Neurocrine Biosciences (NBIX) Earnings Date, Estimates & Call Transcripts $115.71 -1.81 (-1.54%) As of 05/9/2025 04:00 PM Eastern Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Neurocrine Biosciences Earnings Summary Neurocrine Biosciences posted Q1 2025 earnings on May 5, 2025, reporting an EPS of $0.08, which missed analysts' consensus estimates of $0.70 by $0.62. Quarterly revenue rose 11.1% year-over-year to $572.60 million, below the consensus estimate of $587.06 million. With a trailing EPS of $3.29 and a P/E Ratio of 35.17, Neurocrine Biosciences' earnings are expected to grow 51.17% next year, from $4.28 to $6.47 per share. Latest Q1 Earnings DateMay. 5EstimatedConsensus EPS (May. 5) $0.70 Actual EPS (May. 5) $0.08 Missed By -$0.62 Actual Revenue (May. 5) $572.60MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q) Slide DeckSlide DeckFull Screen Slide DeckPowered by Get Neurocrine Biosciences Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurocrine Biosciences and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNBIX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NBIX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Neurocrine Biosciences Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20254-$0.25$1.33$0.74Q2 20254$0.63$1.18$0.99Q3 20254$1.17$1.34$1.26Q4 20254$1.27$1.38$1.33 FY 2025 16 $2.82 $5.23 $4.31 Q1 20262$1.10$1.66$1.38Q2 20262$1.41$1.85$1.63Q3 20262$1.58$1.80$1.69Q4 20262$1.68$2.25$1.97 Neurocrine Biosciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025$0.70$0.08 -$0.62$0.08$587.06M$572.60M2/6/2025Q4 2024$1.62$1.00 -$0.62$1.00$629.40M-8/1/2024Q2 2024$1.15$0.63 -$0.52$0.63$545.98M$590.20M5/1/2024Q1 2024$1.04$0.42 -$0.62$0.42$512.21M$515.30M2/7/2024Q4 2023$1.13$1.44+$0.31$1.44$518.52M$515.20M10/31/2023Q3 2023$0.91$0.82 -$0.09$0.82$479.09M$498.80M8/1/2023Q2 2023$0.77$0.95+$0.18$0.95$448.29M$452.70M Neurocrine Biosciences Earnings - Frequently Asked Questions When did Neurocrine Biosciences announce their last quarterly earnings? Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earning data on Monday, May 5, 2025. Learn more on NBIX's earnings history. Did Neurocrine Biosciences beat their earnings estimates last quarter? In the previous quarter, Neurocrine Biosciences (NASDAQ:NBIX) missed the analysts' consensus estimate of $0.70 by $0.62 with a reported earnings per share (EPS) of $0.08. Learn more on analysts' earnings estimate vs. NBIX's actual earnings. How much revenue does Neurocrine Biosciences generate each year? Neurocrine Biosciences (NASDAQ:NBIX) has a recorded annual revenue of $2.36 billion. How much profit does Neurocrine Biosciences generate each year? Neurocrine Biosciences (NASDAQ:NBIX) has a recorded net income of $341.30 million. NBIX has generated $3.29 earnings per share over the last four quarters. What is Neurocrine Biosciences's price-to-earnings ratio? Neurocrine Biosciences (NASDAQ:NBIX) has a trailing price-to-earnings ratio of 35.17 and a forward price-to-earnings ratio of 27.04. The price/earnings-to-growth ratio is 0.77. What is Neurocrine Biosciences's EPS forecast for next year? Neurocrine Biosciences's earnings are expected to grow from $4.28 per share to $6.47 per share in the next year, which is a 51.17% increase. More Earnings Resources from MarketBeat Related Companies ALNY Earnings Date BIIB Earnings Date UTHR Earnings Date INCY Earnings Date BMRN Earnings Date EXEL Earnings Date EXAS Earnings Date RGEN Earnings Date HALO Earnings Date MDGL Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming?DexCom Stock: Earnings Beat and New Market Access Drive Bull CaseDisney Stock Jumps on Earnings—Is the Magic Sustainable? This page (NASDAQ:NBIX) was last updated on 5/10/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Remember when they said crypto would never go mainstream? Well, something remarkable has happened… Blac...Crypto 101 Media | SponsoredTrump’s Secret WeaponWall Street is nervous. Billionaires are shifting assets. And everyday investors? Most are completely unprepa...American Alternative | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredOne Stock Gold Blueprint to Survive the Market ChaosOne Stock Gold Blueprint to Survive the Market Chaos Markets are volatile, uncertainty is everywhere, and A...InvestorPlace | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts